The company also announced the initiation of its U.S. commercial operations in New York under the leadership of Jeffrey D. Marrazzo, former executive with Generation Health, a genetic benefit management company.
"In the next five years, most cancer patients will have molecular and genomic profiles of their tumors," said Mr. Marrazzo. "MolecularHealth's mature technology platform and clinical and research relationships, including with the M.D. Anderson Cancer Center, will enable us to help physicians and other stakeholders translate this information into the language of the user."
In the coming months, the company will make a series of announcements critical to the advancement of precision medicine.
About MolecularHealthMolecularHealth is on the forefront of precision medicine, applying a pioneering approach called clinico-molecular informatics to patient treatment. The company's knowledge-driven solutions translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer and more effective drug choices. For patients at risk of a serious adverse drug event, or for those awaiting their next course of cancer treatment, precision matters. MolecularHealth's offerings range from a next generation drug safety assessment tool that analyzes the molecular basis of adverse events to the first oncology decision support solution that transforms whole genome sequencing data into evidence-based treatment strategies.
The company maintains offices in Basel, Switzerland; Heidelberg, Germany; Houston and New York and is backed by the co-founder, former chairman and chief executive officer of SAP, Dietmar Hopp. MolecularHealth has successfully built upon its heritage as one of the leading software analysis providers for the Human Genome Project. In 2008, MolecularHealth entered into a ten-year strategic affiliation agreement with The University of Texas M.D. Anderson Cancer Cente
Copyright©2010 PR Newswire.
All rights reserved